Key Points
- Director Stephen Zarrilli sold 25,000 Globus Medical shares at an average price of $87.04, generating $2.176 million. The transaction reduced his ownership by 50% to 25,000 shares.
- Globus Medical exceeded quarterly expectations, reporting $1.34 in earnings per share versus the $1.10 consensus and $789.61 million in revenue. Revenue increased 5.9% year over year, and the company issued fiscal 2026 EPS guidance of $4.95–$5.05.
- Analysts maintain a generally positive outlook, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $101.77. Institutional investors own approximately 95.16% of the company’s shares.
Globus Medical, Inc. (NYSE:GMED - Get Free Report) Director Stephen Zarrilli sold 25,000 shares of the business's stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total value of $2,176,000.00. Following the transaction, the director owned 25,000 shares in the company, valued at $2,176,000. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Globus Medical Price Performance
Shares of GMED stock opened at $88.48 on Thursday. Globus Medical, Inc. has a one year low of $54.15 and a one year high of $101.40. The stock has a market cap of $11.88 billion, a P/E ratio of 22.63, a price-to-earnings-growth ratio of 1.39 and a beta of 0.95. The stock has a fifty day moving average price of $80.35 and a 200 day moving average price of $84.80.
Globus Medical (NYSE:GMED - Get Free Report) last posted its earnings results on Thursday, August 6th. The medical device company reported $1.34 earnings per share for the quarter, beating analysts' consensus estimates of $1.10 by $0.24. The business had revenue of $789.61 million for the quarter, compared to analysts' expectations of $782.88 million. Globus Medical had a net margin of 17.02% and a return on equity of 14.57%. The firm's revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.86 earnings per share. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. Equities research analysts anticipate that Globus Medical, Inc. will post 4.99 EPS for the current year.
Institutional Investors Weigh In On Globus Medical
A number of institutional investors and hedge funds have recently made changes to their positions in the company. Elevation Wealth Partners LLC boosted its stake in shares of Globus Medical by 2,178.6% in the 2nd quarter. Elevation Wealth Partners LLC now owns 319 shares of the medical device company's stock valued at $25,000 after purchasing an additional 305 shares during the last quarter. SBI Securities Co. Ltd. grew its holdings in Globus Medical by 98.2% during the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company's stock worth $29,000 after acquiring an additional 167 shares during the period. Advisory Services Network LLC acquired a new position in shares of Globus Medical in the 3rd quarter valued at $26,000. EverSource Wealth Advisors LLC lifted its stake in shares of Globus Medical by 74.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company's stock valued at $27,000 after purchasing an additional 197 shares during the period. Finally, Larson Financial Group LLC boosted its position in shares of Globus Medical by 83.4% in the 4th quarter. Larson Financial Group LLC now owns 532 shares of the medical device company's stock worth $46,000 after purchasing an additional 242 shares during the last quarter. Institutional investors own 95.16% of the company's stock.
Wall Street Analyst Weigh In
A number of research firms recently weighed in on GMED. Needham & Company LLC raised their price target on Globus Medical from $114.00 to $117.00 and gave the company a "buy" rating in a report on Friday, May 8th. Wall Street Zen downgraded shares of Globus Medical from a "strong-buy" rating to a "buy" rating in a research report on Saturday, May 9th. Truist Financial decreased their price objective on shares of Globus Medical from $115.00 to $100.00 and set a "buy" rating on the stock in a report on Thursday, July 16th. Weiss Ratings restated a "hold (c+)" rating on shares of Globus Medical in a research report on Monday, July 13th. Finally, Piper Sandler dropped their target price on shares of Globus Medical from $115.00 to $100.00 and set an "overweight" rating for the company in a research note on Monday, June 15th. Three equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $101.77.
View Our Latest Report on GMED
About Globus Medical
(
Get Free Report)
Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.
In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
